# Venous Endothelial Cells Promote Osteoblast Differentiation More Effectively Than Arterial Cells via TGF‐β/BMP9 and Notch Pathway‐Related Gene Expression

**Authors:** Célio J. C. Fernandes, Rodrigo A. Foganholi da Silva, Marcel R. Ferreira, Willian F. Zambuzzi

PMC · DOI: 10.1002/cbf.70160 · Cell Biochemistry and Function · 2026-01-16

## TL;DR

Venous endothelial cells better support bone cell development than arterial cells by activating specific signaling pathways and improving the bone environment.

## Contribution

The study reveals that venous endothelial cells promote osteoblast differentiation more effectively than arterial cells through distinct paracrine signaling.

## Key findings

- Venous endothelial cell conditioned media significantly enhance osteoblast differentiation and mineralization.
- HUVECs activate TGF-β/BMP9 and Notch pathways, promoting cytoskeletal remodeling and ECM organization.
- Venous endothelial cells induce a hypoxia–VEGF feedback, supporting angiogenic–osteogenic coupling.

## Abstract

The coupling between angiogenesis and osteogenesis is a key determinant of skeletal homeostasis, yet the influence of endothelial cell origin on osteoblast differentiation remains underexplored. Here, we investigated how venous (HUVECs) and arterial (HCAECs) endothelial cells differentially modulate the osteogenic phenotype of human osteoblasts via paracrine signaling. To better address this issue, the conditioned media (CM) from HUVECs significantly enhanced osteoblast differentiation, as evidenced by increased alkaline phosphatase activity, upregulation of canonical markers such as Runx2, Osterix, and Osteocalcin, and activation of matrix mineralization genes (Tnap, Bsp, Col1a1). In contrast, CM from HCAECs induced a markedly weaker response. qPCR analysis revealed that HUVEC‐CM robustly stimulated key osteoinductive pathways, including TGF‐β/BMP9 and Notch, with pronounced activation of SMADs, Jagged, and Notch receptors. Moreover, HUVEC‐CM promoted cytoskeletal remodeling via increased expression of Integrin‐β1, FAK, Src, and Cofilin, and favored ECM organization by repressing MMP activity and enhancing Reck expression. Hypoxia‐associated markers (Hif1α, Vegf) were also elevated in HUVEC‐treated osteoblasts, supporting enhanced angiogenic‐osteogenic coupling. Principal component and network analyses confirmed a distinct molecular clustering for HUVEC‐responsive genes. Altogether, our data demonstrate that venous endothelial cells, through their specific secretome, provide a more adequate microenvironment for osteoblast differentiation and mineralization compared to their arterial equivalent. These findings underscore the functional relevance of endothelial plasticity in bone regeneration and support the use of venous‐derived endothelial factors in bone tissue engineering strategies.

Bone regeneration depends on precise coupling between angiogenesis and osteogenesis, yet how endothelial origin shapes osteoblast fate is unclear.Here we show that venous endothelial cells (HUVECs) secrete factors that outperform arterial cells (HCAECs) in driving osteoblast differentiation and matrix mineralization, via coordinated activation of TGF‐β/BMP9–SMAD and Notch axes, reinforcement of focal‐adhesion/cytoskeletal programs, and induction of a hypoxia–VEGF feedback.These data identify a venous‐biased paracrine signature that aligns with bone microvascular biology and offers a clear criterion for selecting endothelial sources or secretomes to enhance bone tissue engineering and repair.

Bone regeneration depends on precise coupling between angiogenesis and osteogenesis, yet how endothelial origin shapes osteoblast fate is unclear.

Here we show that venous endothelial cells (HUVECs) secrete factors that outperform arterial cells (HCAECs) in driving osteoblast differentiation and matrix mineralization, via coordinated activation of TGF‐β/BMP9–SMAD and Notch axes, reinforcement of focal‐adhesion/cytoskeletal programs, and induction of a hypoxia–VEGF feedback.

These data identify a venous‐biased paracrine signature that aligns with bone microvascular biology and offers a clear criterion for selecting endothelial sources or secretomes to enhance bone tissue engineering and repair.

## Linked entities

- **Genes:** RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860], SP7 (Sp7 transcription factor) [NCBI Gene 121340], bglap2 (bone gamma-carboxyglutamate (gla) protein (osteocalcin) 2) [NCBI Gene 100493875], ALPL (alkaline phosphatase, biomineralization associated) [NCBI Gene 249], IBSP (integrin binding sialoprotein) [NCBI Gene 3381], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], LOC778901 (protein jagged-1b) [NCBI Gene 778901], Notch (neurogenic locus notch homolog) [NCBI Gene 100616083], PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], CFL1 (cofilin 1) [NCBI Gene 1072], MMP (Muscle moisture percentage) [NCBI Gene 449383], RECK (reversion inducing cysteine rich protein with kazal motifs) [NCBI Gene 8434], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422]

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, RECK (reversion inducing cysteine rich protein with kazal motifs) [NCBI Gene 8434] {aka ST15}, PTK2 (protein tyrosine kinase 2) [NCBI Gene 5747] {aka FADK, FADK 1, FAK, FAK1, FRNK, PPP1R71}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, IBSP (integrin binding sialoprotein) [NCBI Gene 3381] {aka BNSP, BSP, BSP II, BSP-II, SP-II}, SP7 (Sp7 transcription factor) [NCBI Gene 121340] {aka OI11, OI12, OSX, osterix}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, GDF2 (growth differentiation factor 2) [NCBI Gene 2658] {aka BMP-9, BMP9, HHT5}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, Tnap [NCBI Gene 445341], CFL1 (cofilin 1) [NCBI Gene 1072] {aka CFL, HEL-S-15, cofilin}, ITGB1 (integrin subunit beta 1) [NCBI Gene 3688] {aka CD29, FNRB, GPIIA, MDF2, MSK12, VLA-BETA}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}
- **Diseases:** Hypoxia (MESH:D000860)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12809378/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12809378/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12809378/full.md

---
Source: https://tomesphere.com/paper/PMC12809378